Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
ALEMBIC ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALEMBIC Mar-23 |
ADCOCK INGRAM Jun-14 |
ALEMBIC/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 87 | 327 | - | |
Low | Rs | 56 | 236 | - | |
Sales per share (Unadj.) | Rs | 5.0 | 97.3 | - | |
Earnings per share (Unadj.) | Rs | 3.1 | -24.5 | - | |
Cash flow per share (Unadj.) | Rs | 3.4 | -20.3 | - | |
Dividends per share (Unadj.) | Rs | 2.20 | 0 | - | |
Avg Dividend yield | % | 3.1 | 0 | - | |
Book value per share (Unadj.) | Rs | 80.9 | 76.3 | - | |
Shares outstanding (eoy) | m | 256.78 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 14.4 | 2.9 | 497.0% | |
Avg P/E ratio | x | 22.7 | -11.5 | -197.7% | |
P/CF ratio (eoy) | x | 21.0 | -13.9 | -151.2% | |
Price / Book Value ratio | x | 0.9 | 3.7 | 23.9% | |
Dividend payout | % | 70.1 | 0 | - | |
Avg Mkt Cap | Rs m | 18,298 | 47,499 | 38.5% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 240 | 2,981 | 8.1% | |
Avg. sales/employee | Rs Th | 0 | 3,824.0 | - | |
Avg. wages/employee | Rs Th | 0 | 694.4 | - | |
Avg. net profit/employee | Rs Th | 0 | -963.6 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 1,272 | 16,416 | 7.8% | |
Other income | Rs m | 643 | 115 | 559.0% | |
Total revenues | Rs m | 1,915 | 16,531 | 11.6% | |
Gross profit | Rs m | 297 | -2,845 | -10.4% | |
Depreciation | Rs m | 67 | 709 | 9.5% | |
Interest | Rs m | 5 | 445 | 1.0% | |
Profit before tax | Rs m | 868 | -3,883 | -22.4% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 62 | 243 | 25.5% | |
Profit after tax | Rs m | 806 | -4,137 | -19.5% | |
Gross profit margin | % | 23.4 | -17.3 | -134.8% | |
Effective tax rate | % | 7.1 | -6.2 | -113.9% | |
Net profit margin | % | 63.4 | -25.2 | -251.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 1,721 | 12,024 | 14.3% | |
Current liabilities | Rs m | 838 | 6,765 | 12.4% | |
Net working cap to sales | % | 69.4 | 32.0 | 216.7% | |
Current ratio | x | 2.1 | 1.8 | 115.6% | |
Inventory Days | Days | 5,038 | 111 | 4,543.0% | |
Debtors Days | Days | 673 | 124 | 542.8% | |
Net fixed assets | Rs m | 20,324 | 7,009 | 290.0% | |
Share capital | Rs m | 514 | 76 | 673.8% | |
Net worth | Rs m | 20,780 | 12,885 | 161.3% | |
Long term debt | Rs m | 0 | 4,528 | 0.0% | |
Total assets | Rs m | 22,046 | 24,341 | 90.6% | |
Interest coverage | x | 187.7 | -7.7 | -2,427.0% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0.1 | 0.7 | 8.6% | |
Return on assets | % | 3.7 | -15.2 | -24.2% | |
Return on equity | % | 3.9 | -32.1 | -12.1% | |
Return on capital | % | 4.2 | -19.8 | -21.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 389 | 1,401 | 27.7% | |
From Investments | Rs m | 73 | -430 | -17.0% | |
From Financial Activity | Rs m | -464 | 4,110 | -11.3% | |
Net Cashflow | Rs m | -2 | 5,081 | -0.0% |
Compare ALEMBIC With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare ALEMBIC With: KIMIA BIOSCIENCES DESH RAKSHAK AUROBINDO PHARMA HINDUSTAN BIOSCIE NECTAR LIFESCIENCE
After opening the negative note, Indian share markets Slipped further as the session progressed and ended the day weak.